# US 2024/0319196 A1 · Methods for predicting multi-organ metastatic disease and overall and progression free survival in subjects having hyper-engorged circulating cancer associated macrophage-like cells (camls)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0319196 A1
- Document ID: US20240319196A1
- Status: Published application
- Kind: A1
- Application number: 18/576,514
- Filed: 2022-07-06
- Published: 2024-09-26
- Earliest claimed: 2021-07-06
- Assignees: Creatv Micro Tech, Inc.
- Applicants: Creatv Micro Tech Inc.
- Inventors: Daniel L. Adams; Cha-Mei TANG
- Web page: https://patentgrep.com/patent/US20240319196A1

## CPC

- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- G01N 33/56972: {White blood cells}
- G01N 33/6872: {Intracellular protein regulatory factors and their receptors, e.g. including ion channels}
- G01N 2800/50: Determining the risk of developing a disease
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Means for predicting (i) multiple organ metastasis and/or multifocal metastatic disease and (ii) overall survival (OS) and progression free survival (PFS) of subjects having cancer are disclosed, where the predictions are based on the number and size of circulating cancer associated macrophage-like cells (CAMLs) found in a biological sample, such as blood, from the subject.

## Claims

### Claim 1

A method for diagnosing multiple organ metastasis and/or multifocal metastatic disease in a subject, said method comprising determining the size of CAMLs in a biological sample from a subject, such as a subject having cancer, wherein when at least one CAML in said sample is about 100 μm or more in size, the subject is diagnosed to have multiple organ metastases and/or multifocal metastatic disease.

### Claim 2

A method for predicting development of multiple organ metastasis and/or multifocal metastatic disease in a subject, said method comprising determining the size of CAMLs in a biological sample from a subject, such as a subject having cancer, wherein when at least one CAML in said sample is about 100 μm or more in size, the subject is predicted to develop multiple organ metastases and/or multifocal metastatic disease.

### Claim 3

A method for predicting overall survival (OS) and/or progression free survival (PFS) of a subject having cancer, said method comprising determining the size of CAMLs in a biological sample from a subject having cancer, wherein when at least one CAML in said sample is about 100 μm or more in size, the subject is predicted to have shorter OS and/or shorter PFS than a subject having the same or similar cancer but lacking at least one CAML in a corresponding sample about 100 μm or more in size.

### Claim 4

A method for predicting OS and/or PFS of a subject having cancer, said method comprising determining the size of CAMLs in a biological sample from a subject having cancer, wherein when at least one CAML in said sample is about 100 μm or more in size, the OS and/or PFS of the subject is predicted to be less or shorter than a subject having cancer where none of the CAMLs is more than about 100 μm in size.

### Claim 5 (depends on 3)

The method of claim 3, wherein said OS and/or PFS is over a period of at least 12 months.

### Claim 6 (depends on 3)

The method of claim 3, wherein said OS and/or PFS is over a period of at least 24 months.

### Claim 7 (depends on 1)

The method of claim 1, wherein the size of the biological sample is between 5 and 15 mL.

### Claim 8 (depends on 1)

The method of claim 1, wherein the CAMLs have the following characteristics:
(a) large atypical polyploid nucleus of about 14-64 μm in size, or multiple nuclei in a single cell;
(b) cell size of about 20-300 μm in size; and
(c) morphological shape selected from the group consisting of spindle, tadpole, round, oblong, two legs, more than two legs, thin legs, and amorphous.

### Claim 9 (depends on 8)

The method of claim 8, wherein the CAMLs have one or more of the following additional characteristics:
(d) CD14 positive phenotype;
(e) CD45 expression;
(f) EpCAM expression;
(g) vimentin expression;
(h) PD-L1 expression;
(i) monocytic CD11C marker expression;
(j) endothelial CD146 marker expression;
(k) endothelial CD202b marker expression; and
(l) endothelial CD31 marker expression.

### Claim 10 (depends on 1)

The method of claim 1, wherein the source of the biological sample is one or more of peripheral blood, blood, lymph node, bone marrow, cerebral spinal fluid, tissue, and urine.

### Claim 11 (depends on 10)

The method of claim 10, wherein the biological sample is antecubital-vein blood, inferior-vena-cava blood, femoral vein blood, portal vein blood, or jugular-vein blood.

### Claim 12 (depends on 1)

The method of claim 1, wherein the cancer is a solid tumor, Stage I cancer, Stage II cancer, Stage III cancer, Stage IV cancer, carcinoma, sarcoma, neuroblastoma, melanoma, epithelial cell cancer, breast cancer, prostate cancer, lung cancer, pancreatic cancer, colorectal cancer, renal cancer, liver cancer, head and neck cancer, kidney cancer, ovarian cancer, esophageal cancer or other solid tumor cancer.

### Claim 13 (depends on 1)

The method of claim 1, wherein CAMLs are isolated from the biological samples for the determining steps using one or more means selected from the group consisting of size exclusion methodology, immunocapture, red blood cell lysis, white blood cell depletion, FICOLL, electrophoresis, dielectrophoresis, flow cytometry, magnetic levitation, and various microfluidic chips, or a combination thereof.

### Claim 14 (depends on 13)

The method of claim 13, wherein CAMLs are isolated from the biological samples using size exclusion methodology that comprises using a microfilter.

### Claim 15 (depends on 14)

The method of claim 14, wherein the microfilter has a pore size ranging from about 5 microns to about 20 microns.

### Claim 16 (depends on 15)

The method of claim 15, wherein the pores of the microfilter have a round, race-track shape, oval, square and rectangular pore shape.

### Claim 17 (depends on 15)

The method of claim 15, wherein the microfilter has precision pore geometry and uniform pore distribution.

### Claim 18 (depends on 13)

The method of claim 13, wherein CAMLs are isolated using a microfluidic chip via physical size-based sorting, hydrodynamic size-based sorting, grouping, trapping, immunocapture, concentrating large cells, or eliminating small cells based on size.

### Claim 19 (depends on 1)

The method of claim 1, wherein CAMLs are isolated from the biological samples for the determining steps using a low-pressure microfiltration assay.
